CLINUVEL says it has met its recruitment target in its Phase 3 trial (CUV105) of SCENESSE (afamelanotide) in vitiligo, with more than 200 patients enrolled. …
CLINUVEL recruits 200 patients for Phase 3 vitiligo trial of SCENESSE
May 7, 2025 Australian Biotech
Latest Video
New Stories
-
Australia's system is more uniform than the US, but not uniformly better
June 17, 2025 - - Latest News -
Australian company secures FDA approval to progress development of CAR-T therapy
June 16, 2025 - - Latest News -
These systems are and always have been more similar than most realise
June 16, 2025 - - Latest News -
Confirmation the UK has agreed to review medicine prices in response to US demand
June 16, 2025 - - Latest News -
Amplia says pathological complete response in patient from ACCENT trial
June 16, 2025 - - Australian Biotech -
This could be the canary in the coal mine, but a lot of canaries have already died
June 15, 2025 - - Latest News -
'There is a very real impact on Australian patients and clinicians'
June 15, 2025 - - Latest News